CanFite Biopharma (CANF)
(Delayed Data from AMEX)
$2.25 USD
-0.10 (-4.26%)
Updated Oct 10, 2024 04:00 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for CanFite Biopharma Ltd falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 9 | 8 | 19 | 8 | 3 |
Receivables | 0 | 0 | 1 | 1 | 4 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 1 | 0 | 0 | 0 |
Total Current Assets | 10 | 9 | 20 | 9 | 7 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 1 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 10 | 9 | 20 | 10 | 8 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 2 | 2 | 1 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 1 | 1 | 0 | 0 |
Total Current Liabilities | 2 | 3 | 3 | 1 | 3 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 2 | 2 | 3 | 2 | 2 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 2 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 4 | 5 | 6 | 3 | 7 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 61 | 33 | 8 |
Capital Surplus | 164 | 154 | 93 | 97 | 96 |
Retained Earnings | -158 | -151 | -141 | -125 | -110 |
Other Equity | 1 | 1 | 1 | 1 | 7 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 6 | 4 | 14 | 6 | 1 |
Total Liabilities & Shareholder's Equity | 10 | 9 | 20 | 10 | 8 |
Total Common Equity | 6 | 4 | 14 | 6 | 1 |
Shares Outstanding | 3.50 | 3.30 | 2.70 | 1.50 | 0.10 |
Book Value Per Share | 1.78 | 1.35 | 5.33 | 4.05 | 8.80 |
Fiscal Year End for CanFite Biopharma Ltd falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 5 | -99,999 | 9 | 8 |
Receivables | NA | NA | NA | 0 | NA |
Notes Receivable | NA | NA | NA | 0 | NA |
Inventories | NA | NA | NA | 0 | NA |
Other Current Assets | NA | 1 | NA | 1 | 1 |
Total Current Assets | NA | 6 | NA | 10 | 9 |
Net Property & Equipment | NA | 0 | NA | 0 | 0 |
Investments & Advances | NA | NA | NA | 0 | NA |
Other Non-Current Assets | NA | NA | NA | 0 | NA |
Deferred Charges | NA | NA | NA | 0 | NA |
Intangibles | NA | NA | NA | 0 | NA |
Deposits & Other Assets | NA | NA | NA | 0 | NA |
Total Assets | NA | 6 | NA | 10 | 9 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | NA | 0 | NA |
Accounts Payable | NA | 1 | NA | 1 | 1 |
Current Portion Long-Term Debt | NA | NA | NA | 0 | NA |
Current Portion Capital Leases | NA | NA | NA | 0 | NA |
Accrued Expenses | NA | NA | NA | 0 | NA |
Income Taxes Payable | NA | NA | NA | 0 | NA |
Other Current Liabilities | NA | 1 | NA | 1 | 1 |
Total Current Liabilities | NA | 2 | NA | 2 | 2 |
Mortgages | NA | NA | NA | 0 | NA |
Deferred Taxes/Income | NA | 1 | NA | 2 | 2 |
Convertible Debt | NA | NA | NA | 0 | NA |
Long-Term Debt | NA | NA | NA | 0 | NA |
Non-Current Capital Leases | NA | NA | NA | 0 | NA |
Other Non-Current Liabilities | NA | NA | 0 | NA | |
Minority Interest (Liabilities) | NA | NA | NA | 0 | NA |
Total Liabilities | NA | 3 | NA | 4 | 4 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | NA | 0 | NA |
Common Stock (Par) | NA | NA | NA | 0 | NA |
Capital Surplus | NA | 164 | NA | 164 | 161 |
Retained Earnings | NA | -162 | NA | -158 | -157 |
Other Equity | NA | 1 | NA | 1 | 1 |
Treasury Stock | NA | NA | NA | 0 | NA |
Total Shareholder's Equity | NA | 2 | NA | 6 | 5 |
Total Liabilities & Shareholder's Equity | NA | 6 | NA | 10 | 9 |
Total Common Equity | 0 | 100,001 | 0 | 6 | 100,004 |
Shares Outstanding | 3.50 | 3.50 | 3.50 | 3.50 | 3.50 |
Book Value Per Share | 0.00 | 28,571.85 | 0.00 | 1.78 | 28,572.64 |